Immune checkpoint inhibitors (ICI) such as cytotoxic T-lymphocyte antigen 4 (CTLA-4), programmed cell death 1 (PD-1), and programmed cell death ligand 1 (PD-L1) are increasingly prevalent in the treatment of a plethora of cancer types. The gene discussed is CD274; the disease is cancer.